About
Male
Chris is the Chief Investment Officer of Syncona Investment Management Ltd. He is currently Chairman at five Syncona companies: NightStar Therapeutics (NASDAQ:NITE), Freeline Therapeutics, Gyroscope Therapeutics, Swan Therapeutics and Orbit Biomedical. He has been instrumental in their foundation and development including the acquisition of a gene therapy manufacturing platform from Rentschler Biotechnologie on behalf of Freeline. Previously, he was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.
Experience
Syncona Partners LLP
View →Chief Investment Officer · 2012 – present
IPO31London, England, United KingdomBiotechnology · Financial Services
Apposite Capital
View →Partner · 2007 – 2012
31London, England, United KingdomFinancial Services · Health Care
- Board Member · Spur Therapeutics2024 – present
- Board Director · Zonare Medical Systems2009 – present
- Chairman · Freeline
- Chairman · Gyroscope Therapeutics
Education
- University of Cambridge · PhD, Organic Chemistry1998 – 2001
- University of Cambridge · Ph.D, Organic Chemistry– 2001
People at Syncona Partners LLP
Data from: crunchbase
